Calciphylaxis: A devastating complication of derangements of calcium-phosphorus metabolism- A case report and review of the literatura.
Sato, "A case-control study of
calciphylaxis in Japanese end-stage renal disease patients," Nephrology Dialysis Transplantation, vol.
Wong, "
Calciphylaxis in patients on hemodialysis: a prevalence study," Surgery, vol.
Skin diseases that were studied and evaluated are detailed in Table 1 but also included the following: perforating disorders;
calciphylaxis; porphyria and pseudoporphyria; onychomycosis; clubbing; horizontal nail ridging; Terry's nail; hypersensitivity rashes; and malignant skin lesions.
Calcific uremic arteriolopathy (CUA) is the preferred and more descriptive term for what was pre viously known as
calciphylaxis. It occurs in patients with end stage renal disease.
Calciphylaxis is a rare disorder in patients with chronic renal failure that is characterized by ischemic necrotic skin lesions.
Some reviews were conducted on nursing interventions to achieve patient outcomes on topics such as fatigue interventions (Astroth, Russell, & Welch, 2013);
calciphylaxis (Carter & Ratnam, 2013), cannulation outcomes (Harwood et al., 2017), music and anxiety (Kim et al., 2015), and complementary pain therapies (Zins et al., 2018).
Calciphylaxis or calcifc uremic arteriolopathy is a severe complication of advanced chronic kidney disease (CKD) and other risk factors, including female gender, Caucasian race, obesity, diabetes mellitus, systemic autoimmune and liver diseases, elevated levels of calcium-phosphate product, hypercoagulable diseases, and therapy with calcium and vitamin D analogues, warfarin, corticosteroid drugs, and immunosuppressive drugs (1).